Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Spexis AG
  6. Summary
    POLN   CH0106213793

SPEXIS AG

(POLN)
 SummaryQuotesChartsNewsCompany 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/21/2022 01/24/2022 01/25/2022 01/26/2022 01/27/2022 Date
1.79(c) 1.624(c) 1.648(c) 1.78(c) 1.65 Last
20 074 45 653 3 135 1 836 14 662 Volume
-0.44% -9.27% +1.48% +8.01% -7.30% Change
More quotes
Company
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with... 
Sector
Pharmaceuticals
Calendar
-
More about the company
All news about SPEXIS AG
2021Polyphor Finalizes Merger With EnBiotix, to Change Name to Spexis
MT
2021Polyphor closes merger with EnBiotix and is renamed Spexis
EQ
2021EnBiotix, Inc. completed the acquisition of Polyphor AG from Novartis Venture Funds, Va..
CI
2021EnBiotix, Inc. Closes $11M Pre-Merger Financing
AQ
2021Polyphor To Close EnBiotix Merger Before 2021-End
MT
2021Polyphor to inform about the financing of its merger partner EnBiotix
EQ
2021Polyphor Treats First Patient in Early-Stage Study of Inhaled Antibiotic
MT
2021Polyphor and EnBiotix announce dosing of first patient in a first-in-human clinical tri..
EQ
2021Polyphor and Enbiotix Announces Dosing of First Patient in a First-In-Human Clinical Tr..
CI
2021Polyphor, EnBiotix Shareholders Green-Light Merger, Name Change
MT
2021Polyphor AG Announces Executive Changes
CI
2021POLYPHOR : Exempted From Public Tender Offer Obligation In Merger With EnBiotix
MT
2021Polyphor to Seek Acquisitions
CI
2021Polyphor AG Announces Executive Changes
CI
2021POLYPHOR : Wraps Up Sale Of Inhaled Murepavadin To EnBiotix
MT
More news
News in other languages on SPEXIS AG
01/06BOURSE ZURICH : la chasse aux records reprend avant la fin d'année
01/06BOURSE ZURICH : hésitante à l'entame de la dernière séance de l'année
01/06Polyphor schliesst Fusion mit Enbiotix ab und wird in Spexis umbenannt
01/06AKTIEN SCHWEIZ SCHLUSS : SMI gibt leicht nach - Konsolidierung auf hohem Niveau
01/06BOURSE ZURICH : dans le rouge pour l'avant-dernière séance de l'année
More news
Chart SPEXIS AG
Duration : Period :
Spexis AG Technical Analysis Chart | POLN | CH0106213793 | MarketScreener
Technical analysis trends SPEXIS AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Managers and Directors
G÷khan Batur Chief Executive Officer
Hernan Levett Chief Financial Officer
Kuno Sommer Chairman
Frank T. Weber Chief Medical & Development Officer
Bernard Bollag Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SPEXIS AG6.59%92
CSL LIMITED-11.13%88 612
WUXI BIOLOGICS (CAYMAN) INC.-13.88%43 139
SAMSUNG BIOLOGICS CO.,LTD.-16.17%41 851
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-8.47%32 258